tldrdaily.news logo
Tag

Boston Scientific

All articles tagged with #boston scientific

business-and-finance2 years ago

Boston Scientific's $3.7 Billion Acquisition of Axonics

Boston Scientific has agreed to acquire Axonics for approximately $3.7 billion, aiming to strengthen its urology business and expand into the high-growth sacral neuromodulation market. Axonics, based in California, develops neuromodulation systems for urinary and bowel dysfunction treatment. The acquisition is expected to be completed in the first half of 2024, with Boston Scientific projecting a highly accretive impact on its urology business in 2024. This move aligns with Boston Scientific's strategy of pursuing M&A to reinforce category leadership and enter faster growth markets.

via Mass Device|
#acquisition#axonics#boston-scientific
business2 years ago

"Boston Scientific to Acquire Axonics, Inc. in New Agreement"

Boston Scientific has agreed to acquire Axonics, Inc. for approximately $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' product portfolio includes sacral neuromodulation (SNM) therapy systems for overactive bladder and fecal incontinence, with the recent FDA approval of its fourth-generation neurostimulator. The acquisition is expected to strengthen Boston Scientific's ability to serve urologists and provide opportunities to expand access to care for patients. The transaction is anticipated to be completed in the first half of 2024 and is expected to have a highly accretive impact on Boston Scientific's urology business in 2024.

via PR Newswire|
#acquisition#axonics#boston-scientific
healthcare2 years ago

Boston Scientific Acquires Relievant Medsystems for $850M in Back Pain Ablation Tech Deal

Boston Scientific has announced its agreement to acquire Relievant Medsystems, a medical technology company specializing in treating chronic low back pain. The acquisition will expand Boston Scientific's neuromodulation portfolio and provide more treatment options for individuals with vertebrogenic pain. The transaction includes an upfront cash payment of $850 million, with additional contingent payments based on sales performance. The Intracept Intraosseous Nerve Ablation System developed by Relievant is the only FDA-cleared system for vertebrogenic pain and offers a minimally invasive outpatient procedure. The deal is expected to close in the first half of 2024.

via PR Newswire|
#acquisition#boston-scientific#chronic-low-back-pain
healthcare2 years ago

Boston Scientific's Breakthrough in Atrial Fibrillation Treatment Propels Stock Surge

Boston Scientific is expected to receive FDA approval for its pulsed field ablation method of treating abnormal heartbeats, which uses electrical pulses to selectively kill problematic cardiac cells. In a comparison with thermal ablation, the newer approach showed similar efficacy and safety profiles. The company's stock surged 6% on the news. Analysts believe that this development positions Boston Scientific to capture a significant share of the nearly $8 billion electrophysiology market.

via Investor's Business Daily|
#abnormal-heartbeats#boston-scientific#electrophysiology-market
business2 years ago

"Stocks Soaring: 3M, XPeng, Boston Scientific, and More Make Big Moves"

RPT Realty shares surged 17% after Kimco Realty announced its acquisition of the real estate investment trust in a $2 billion all-stock deal. Mister Car Wash stock advanced 6.1% following an upgrade by Piper Sandler. Boston Scientific jumped nearly 6% after announcing positive results for its treatment for abnormal heartbeats. CrowdStrike fell 3.7% after a downgrade by Morgan Stanley. 3M saw a 5.2% increase in its stock price after reaching a tentative deal to settle lawsuits over its combat ear plugs. Xpeng, the Chinese electric car company, rose 5.3% after acquiring Didi's smart electric car development business.

via CNBC|
#3m#boston-scientific#business
business2 years ago

Boston Scientific Takeover Talks Cause SWAV Stock to Plummet.

The potential deal between Boston Scientific and Shockwave Medical reportedly fell apart due to disagreement on price, causing Shockwave's stock to drop by 6.3%. The deal could have bolstered Boston Scientific's cardiovascular portfolio with Shockwave's intravascular lithotripsy technology. Shockwave is expected to report a 103% increase in earnings and a 57% increase in sales for Q1. Analysts predict Shockwave's earnings to increase by 35% and sales to surge by 37% for the year.

via Investor's Business Daily|
#boston-scientific#business#cardiovascular-portfolio